ADVANZ

Serial Number 97671247
732

Registration Progress

Application Filed
Nov 10, 2022
Under Examination
Jul 9, 2024
Approved for Publication
May 14, 2024
Published for Opposition
May 14, 2024
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Jul 09, 2026 158 days

Trademark Image

ADVANZ

Basic Information

Serial Number
97671247
Filing Date
November 10, 2022
Published for Opposition
May 14, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
732
Status Date
Jan 8, 2026
Application
Pending
Classes
005 010

Rights Holder

Mercury Pharma Group Limited

03
Address
Dashwood House
69 Old Broad Street
London EC2M1QS
GB

Ownership History

Mercury Pharma Group Limited

Original Applicant
03
London GB

Mercury Pharma Group Limited

Owner at Publication
03
London GB

Legal Representation

Attorney
Caroline Duncan

USPTO Deadlines

Next Deadline
158 days remaining
NOA E-Mailed - SOU Required
Due Date
July 09, 2026
Extension Available
Until January 09, 2027

Application History

47 events
Date Code Type Description Documents
Jan 9, 2026 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 8, 2026 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jan 8, 2026 EXT3 S SOU EXTENSION 3 FILED Loading...
Jan 8, 2026 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 5, 2026 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Jan 5, 2026 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jan 5, 2026 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jan 5, 2026 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jul 10, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 9, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jul 9, 2025 EXT2 S SOU EXTENSION 2 FILED Loading...
Jul 9, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 4, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 9, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jan 9, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Jan 9, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 9, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
May 14, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 14, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 24, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 9, 2024 EXPT T EXPARTE APPEAL TERMINATED Loading...
Apr 9, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 12, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 12, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 12, 2024 ALIE A ASSIGNED TO LIE Loading...
Oct 24, 2023 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Oct 24, 2023 EXPI T EX PARTE APPEAL-INSTITUTED Loading...
Oct 24, 2023 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
Oct 24, 2023 EXAF T EXPARTE APPEAL RECEIVED AT TTAB Loading...
Sep 27, 2023 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Sep 27, 2023 GNFR O FINAL REFUSAL E-MAILED Loading...
Sep 27, 2023 CNFR R FINAL REFUSAL WRITTEN Loading...
Aug 17, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 16, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 16, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 16, 2023 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
May 16, 2023 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Feb 16, 2023 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED Loading...
Feb 16, 2023 GPRA O PRIORITY ACTION E-MAILED Loading...
Feb 16, 2023 CPRA R PRIORITY ACTION WRITTEN Loading...
Jan 19, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jan 19, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 19, 2023 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jan 19, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jan 18, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 30, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 14, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
A full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus and instruments, and surgical implants comprised of human and animal tissue; all of the foregoing excluding anti-infective pharmaceutical preparations
Class 010
Medical devices, namely, lasers and fibre-optic wires and cables for use in photodynamic therapy with the administration of a photosensitizing agent for the treatment of cancer

Classification

International Classes
005 010